Mechanism of Action and Efficacy of Wu-Hua-Yan-Xiao in the Treatment of Pediatric Acute Pharyngitis Based on Network Pharmacology and Experimental Validation.

IF 4.7 2区医学 Q1 CHEMISTRY, MEDICINAL

Drug Design, Development and Therapy Pub Date : 2025-05-24 eCollection Date: 2025-01-01 DOI:10.2147/DDDT.S513073

Xinyun Zhang, Zengyu Zhang, Yingzi Xu, Jiawei Luo, Zihao Shen, Hao Liang, Yidi Zeng, Wanghua Liu, Caixing Zheng, Jinxia Li

{"title":"Mechanism of Action and Efficacy of Wu-Hua-Yan-Xiao in the Treatment of Pediatric Acute Pharyngitis Based on Network Pharmacology and Experimental Validation.","authors":"Xinyun Zhang, Zengyu Zhang, Yingzi Xu, Jiawei Luo, Zihao Shen, Hao Liang, Yidi Zeng, Wanghua Liu, Caixing Zheng, Jinxia Li","doi":"10.2147/DDDT.S513073","DOIUrl":null,"url":null,"abstract":"Ethnopharmacological relevance: Wu-Hua-Yan-Xiao (WHYX) is an innovative volatile oil formulation derived from the traditional Yinqiao-Mabo decoction, developed for the treatment of pediatric acute pharyngitis.Materials and methods: Network pharmacology was utilized to identify active components and potential therapeutic targets of WHYX in acute pharyngitis. Compounds in WHYX were characterized using UHPLC-QE-MS. A pediatric acute pharyngitis rat model was established by administering 25% ammonia to the pharyngeal mucosa of young rats. WHYX was delivered via aerosol inhalation at gradient concentrations. Histopathological changes in pharyngeal tissues were evaluated by H&E staining. Serum levels of IL-6, IL-1β, TNF-α, and PGE2 were quantified by ELISA. Expression levels of TNF-α, TP53, IL17A, IL6, and Bcl-2 were assessed by qRT-PCR and Western blotting. Apoptosis was analyzed through immunofluorescence staining for Caspase-3 and TUNEL.Results: Network pharmacology identified 130 active compounds and 600 gene targets, with 194 overlapping drug-disease targets. TP53 signaling emerged as a central regulatory pathway. Compared with the model group, the high-dose WHYX volatile oil group showed marked improvements in pharyngeal pathology, significant reductions in inflammatory cytokines, downregulation of TNF-α, TP53, IL17A, IL6, and Bcl-2 expression, and suppressed apoptosis (P < 0.05). Therapeutic effects were comparable to or exceeded those observed in the positive control group. (P < 0.05).Conclusion: The WHYX formula alleviates inflammation, reduces apoptosis, and protects pharyngeal tissue in young rats with acute pharyngitis. Aerosol inhalation of WHYX presents a direct, effective, and non-invasive strategy for pediatric acute pharyngitis management.","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"4321-4342"},"PeriodicalIF":4.7000,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12120256/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S513073","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Ethnopharmacological relevance: Wu-Hua-Yan-Xiao (WHYX) is an innovative volatile oil formulation derived from the traditional Yinqiao-Mabo decoction, developed for the treatment of pediatric acute pharyngitis.

Materials and methods: Network pharmacology was utilized to identify active components and potential therapeutic targets of WHYX in acute pharyngitis. Compounds in WHYX were characterized using UHPLC-QE-MS. A pediatric acute pharyngitis rat model was established by administering 25% ammonia to the pharyngeal mucosa of young rats. WHYX was delivered via aerosol inhalation at gradient concentrations. Histopathological changes in pharyngeal tissues were evaluated by H&E staining. Serum levels of IL-6, IL-1β, TNF-α, and PGE2 were quantified by ELISA. Expression levels of TNF-α, TP53, IL17A, IL6, and Bcl-2 were assessed by qRT-PCR and Western blotting. Apoptosis was analyzed through immunofluorescence staining for Caspase-3 and TUNEL.

Results: Network pharmacology identified 130 active compounds and 600 gene targets, with 194 overlapping drug-disease targets. TP53 signaling emerged as a central regulatory pathway. Compared with the model group, the high-dose WHYX volatile oil group showed marked improvements in pharyngeal pathology, significant reductions in inflammatory cytokines, downregulation of TNF-α, TP53, IL17A, IL6, and Bcl-2 expression, and suppressed apoptosis (P < 0.05). Therapeutic effects were comparable to or exceeded those observed in the positive control group. (P < 0.05).

Conclusion: The WHYX formula alleviates inflammation, reduces apoptosis, and protects pharyngeal tissue in young rats with acute pharyngitis. Aerosol inhalation of WHYX presents a direct, effective, and non-invasive strategy for pediatric acute pharyngitis management.

查看原文本刊更多论文

五化炎消治疗小儿急性咽炎的作用机制及疗效研究——基于网络药理学及实验验证。

民族药理学相关性：五化炎消（WHYX）是一种创新的挥发油配方，衍生自传统的银翘麻柏汤，用于治疗小儿急性咽炎。材料与方法：利用网络药理学方法，鉴定白灵灵治疗急性咽炎的有效成分及潜在治疗靶点。采用UHPLC-QE-MS对WHYX中的化合物进行了表征。采用25%氨灌胃法建立小儿急性咽炎大鼠模型。WHYX以梯度浓度通过气溶胶吸入给药。H&E染色评价咽组织病理变化。ELISA法测定血清IL-6、IL-1β、TNF-α、PGE2水平。采用qRT-PCR和Western blotting检测TNF-α、TP53、IL17A、IL6、Bcl-2的表达水平。免疫荧光染色Caspase-3和TUNEL分析细胞凋亡。结果：网络药理学鉴定出130种活性化合物和600个基因靶点，其中194个药物-疾病重叠靶点。TP53信号作为中心调控途径出现。与模型组比较，高剂量WHYX挥发油组小鼠咽部病理明显改善，炎症因子明显降低，TNF-α、TP53、IL17A、IL6、Bcl-2表达下调，细胞凋亡抑制（P < 0.05）。治疗效果与阳性对照组相当或超过。（p < 0.05）。结论：WHYX方对幼年大鼠急性咽炎有减轻炎症、减少细胞凋亡、保护咽部组织的作用。雾化吸入WHYX为小儿急性咽炎的治疗提供了一种直接、有效和非侵入性的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Design, Development and Therapy CHEMISTRY, MEDICINAL-PHARMACOLOGY & PHARMACY

CiteScore

9.00

自引率

0.00%

发文量

382

审稿时长

>12 weeks

期刊介绍： Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications. The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas. Specific topics covered by the journal include: Drug target identification and validation Phenotypic screening and target deconvolution Biochemical analyses of drug targets and their pathways New methods or relevant applications in molecular/drug design and computer-aided drug discovery* Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes) Structural or molecular biological studies elucidating molecular recognition processes Fragment-based drug discovery Pharmaceutical/red biotechnology Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products** Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing) Preclinical development studies Translational animal models Mechanisms of action and signalling pathways Toxicology Gene therapy, cell therapy and immunotherapy Personalized medicine and pharmacogenomics Clinical drug evaluation Patient safety and sustained use of medicines.